61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL
Jacobson, I., Yoshida, E.M., Sulkowski, M., Nelson, D.R., Svarovskaia, E., An, D., McNally, J., Brainard, D.M., Symonds, W.T., McHutchison, J.G., Pianko, S., Kowdley, K.V.Volume:
58
Language:
english
Journal:
Journal of Hepatology
DOI:
10.1016/S0168-8278(13)60063-X
Date:
April, 2013
File:
PDF, 60 KB
english, 2013